Supplementary Information for:

Genetically Encoded Fragment-Based Discovery of Glycopeptide Ligands for Carbohydrate-Binding Proteins

Simon Ng, Edith Lin, Pavel I. Kitov, Katrina F. Tjhung, Oksana O. Gerlits, Lu Deng, Brian Kasper, Amika Sood, Beth M. Paschal, Ping Zhang, Chang-Chun Ling, John S. Klassen, Christopher J. Noren, Lara K. Mahal, Robert J. Woods, Leighton Coates, Ratmir Derda*

∗Corresponding author: ratmir@ualberta.ca

Table of Contents (click on topic)

Abbreviation

Figure S1. Overview of the workflow of ligand search.

The entire ligand search could be accomplished within a week. a) Modification of phage library and subsequent purification by dialysis required a day. b) Incubation of the modified library with targets on 96-well plate (yellow, 2 h); washing of plate (red, 0.5 h); elution and phage amplification (blue, 5 h); isolation of phage ssDNA (grey, 1 h); PCR of library DNA with 15-barcoded primers, E-Gel purification and template preparation on Ion OneTouchTM 2 System (green, one day); DNA sequencing with Ion PGM[™] System (magenta, one day).

Table S1. Complete list of peptide sequences identified from three sets of volcano plot.

From the first round of selection using Man-X7 library, a total of 86 peptide sequences was identified and they reside at the "intersection" of three pair-wise volcano analysis (see Figure 2B).

Figure S2. Inhibition curves of Man-X₇ conjugates.

Inhibitions of ConA (200 µg/mL) binding to the dextran-coated surface (CM5 chip) were measured with surface plasmon resonance using Man-X₇ conjugates or methyl α -D-mannopyranoside (MeMan) as the inhibitor. IC_{50} values with standard error were measured in three independent experiments.

Figure S3. Inhibition curves of Man-WYNSFGT and SWYNSFGT.

Inhibitions of ConA (200 µg/mL) binding to the dextran-coated surface (CM5 chip) were measured with surface plasmon resonance using Man- X_7 conjugate, Ser- X_7 or MeMan as the inhibitor. IC₅₀ of SWYNSFGT was not determined (n.d.) due to insignificant inhibition even with inhibitor concentration as high as 1 mM . IC₅₀ values with standard error were measured in three independent experiments.

Figure S4. Inhibition curves of control ligands.

Inhibitions of ConA (200 µg/mL) binding to the dextran-coated surface (CM5 chip) were measured with surface plasmon resonance using Man- X_6 conjugates or MeMan as the inhibitor. These conjugates have IC₅₀ values similar to that of MeMan suggested that the inhibition mainly stem from the mannopyranosyl moiety and is independent of the peptide moiety. IC₅₀ values with standard error were measured in three independent experiments.

Raw data obtained for 42 injections of ligands (2 mM for **L9.2**, **L20.2**; 5 mM for **L8.1**; and 10 mM for **L9.1**, **L11.1** and **L20.1**) into a solution of ConA (0.1 mM−0.20 mM) at 4-min intervals and 30 °C. The integrated curve showed experimental points (\blacksquare) and the best fit $(-)$ to the points by a nonlinear leastsquares regression algorithm. The fitting were performed by fixing the stoichiometry of binding to one. It is important to note that, the determination of Ka , ΔH and ΔS in these experiments are inaccurate since they were performed with *c* values much lower than one, because the preparation of ConA with concentration \gg 1 mM is difficult due to solubility issue. In these cases, it is safe to assume that the K_D values of these peptide fragments are much greater than 1 mM.

Figure S6. Examples of raw ITC data of ConA binders.

Selected examples of raw data obtained for 42 injections of ligands (2 mM for **L4**, **L5**, **L10**, **L14**, and **L20**; 1 mM for **L30**, **L33** and **L37**; and 10 mM for **L1**) into a solution of ConA (0.07 mM−0.30 mM) at 4-min intervals and 30 °C. The integrated curve showed experimental points (\blacksquare) and the best fit $(-)$ to the points by a nonlinear least-squares regression algorithm.

The two equivalent Man residues (labeled with "M"), originated from Man-WYD (left) or Man3 (right), displayed equivalent hydrogen-bonding patterns (Arg228 NH to O3, Asn14 side chain NH to O4, Leu99 NH to O5, and Tyr100 NH to O6). In contrast to Man3, the Man-WYD forms few additional hydrogen bonds, and prefers to van der Waals contacts with the protein surface. This is as shown by a higher contact area of synthetic ligand (662 Å) compared to the trisaccharide Man3 (204 Å).

Figure S8**. Binding free energy analysis of ConA bound to Man-WYD.**

Strength of interaction energies scaled from red (strongest) to blue (weakest) in the protein (left) and in the ligand, with percent contribution shown in parentheses (right).

Table S2. Binding free energy analysis estimated by MD simulation.

Average per-residue binding energy^[a] contributions for key^[b] residues in the protein and the ligand

^[a] In kcal/mol

^[b] Residues that contribute greater than 0.5 kcal/mol to the total binding energy.

We hypothesized that oxime functionality might be involved in molecular recognition. STD-NMR^{[\[1\]](#page-101-1)} detected significant contacts between ConA and the protons of the oxime, as well as Tyr and Trp of **L20** and **L15.** Both oxime and the aromatic rings play significant roles in the interaction of the ligand with the protein (Figure 3). The same protons in the control ligand (**L20.3**) exhibited much weaker signal in the STD-NMR, and, thus, significantly less contact with the protein. These results were in-line with the ITC measurements and crystallographic data. The shortened linker ablates the geometry necessary for synergistic binding. To facilitate the ligand comparison, Man H1 of **L20.3** was set as the reference and normalized to 42% (same for **L20** and **L15**). The relative STD effects for other protons were then calculated based on this reference proton. The STD effect of Trp $H\alpha$ was not determined due to the complete attenuation of its signals by WATERGATE W5 sequence.^{[\[2\]](#page-101-2)}

Figure S10. Lectin microarray analysis.

Z-scores for mannose-binding lectins from a lectin microarray incubated with 1.85 µM Cy3-labeled Man-WYK-OH are shown. The $p < 0.01$ cutoff is indicated (red dashed line, Z=1.95). Of the 85 lectins tested, only ConA, LcH, and PSA met this significance threshold, while other mannose-binding proteins (GNA, GRFT, HHL, NPA, SVN, and VVA, see Table S3 for details) did not.

 $\mathsf{c})$

Aligned fragment corresponding to positions 123-237 in ConA:

Where green marks exact match, blue $-$ highly conservative substitution, grey $$ conservative substitution.

Figure S11. Sequence and structure homology of ConA/LcH or ConA/PSA.

a) Superimposition of Man-WYD−ConA complex (red, PDB: 4CZS) with the Glc−LcH complex (blue, PDB: 1LEM), generated by aligning the protein backbone atoms (RMSD = 0.81 Å). b) Superimposition of Man-WYD:ConA complex (red, PDB: 4CZS) with the Man−PSA complex (yellow, PDB: 1RIN), generated by aligning the protein backbone atoms (RMSD = 0.76 Å). c) Multiple sequence alignment of ConA (PDB: 1CVN), PSA (PDB: 1RIN), and LcH (PDB: 1LEM) using Clustal Omega from EMBL- $EBI.^[3]$ $EBI.^[3]$ $EBI.^[3]$

Figure S12. Raw ITC data of MeMan, Man-WYDLF, and Man3-X binding to ConA, LcH and PSA. Raw data obtained for 42 injections of ligands (10 mM for MeMan; 1−4 mM for Man-WYDLF; 1−5 mM for Man3-X) into a solution of ConA (0.19 mM), LcH (0.24 mM) or PSA (0.09 mM) at 4-min intervals and 30 °C. The integrated curve showed experimental points (\blacksquare) and the best fit $(-)$ to the points by a nonlinear least-squares regression algorithm. The stoichiometry parameter, N, was fixed at 1.0 for $c \le 1$ but allowed to float freely for $c > 1$. The K_D of MeMan binding to ConA, LcH or PSA measured on our hands at 30 °C correlate linearly with the literature values measured at 19 °C, i.e., ConA: 140 µM vs. 83 μ M,^{[\[4\]](#page-101-4)} LcH: 2 mM vs. 1.2 mM,^[4] and PSA: 1 mM vs. 0.5 mM.^[4]

Figure S13. ESI-MS binding measurement for DC-SIGN.

The mass spectra of ESI-MS binding measurement for DC-SIGN. Top spectrum: Man-WYD (**L20**); bottom spectrum: Man-NL-WYD (**L20.3**). The measured K_D of **L20** and **L20.3** are 600 \pm 7 μ M and 1890 \pm 40 µM respectively.

Figure S14. Inhibition curves of ConA and DC-SIGN mediated by MeMan, Man-WYDLF and Man3-X.

MeMan, Man-WYDLF, and Man3-X competitively inhibit the binding of glycoprotein probe, horseradish peroxidase (HRP), which contains trimannoside core, to immobilized ConA (left panel) or immobilized tetrameric extracellular domain of DC-SIGN (right panel). The monosaccharide couples synergistically with the peptide fragment and decreases the half maximal inhibitory concentration (IC_{50}) by more than 50-fold for ConA but only 2-fold for DC-SIGN. The results indicate a selective activity enhancement of the peptide fragment for ConA. The absorbance at 450 nm (OD = optical density) is a mean value measured in three independent wells with the error represents one standard deviation of the mean.

b)

Figure S15. Summary of thermodynamic data and affinity.

a) Enthalpy and entropy of the binding of glycopeptides and MeMan to ConA measured with ITC. Orange diamonds (\blacklozenge) are MeMan (n = 5). Blue circles (\blacklozenge) are ligands selected from first round. Green circles (\bullet) are truncations of ligands from the first round. Red squares (\blacksquare) are ligands selected from second round (affinity maturation) and their truncations. b) Summarized table of the K_D of ligand interaction with ConA derived from the ITC data.

Figure S16. Positional abundance of amino acids in phage-displayed peptide libraries.

(A) To demonstrate that the enrichment of a specific amino acid in a specific location does not result from sequence bias in chemically-modified libraries, we compared amino acid composition in a population selected against ConA (blue) to naïve population (green) and biotin-modified population (crimson). The population selected against ConA was obtained as described in the main text. To analyze the sequences present in the chemically-modified population, we oxidized the library, ligated aminooxy biotin (AOB), captured the biotinylated phage on streptavidin-coated beads and deep-sequenced the captured population (ca. 10^8 clones). In these conditions, all biotin-modified phage should be captured and sequenced irrespective of their displayed peptides. To sequence naïve library, we isolated and deep-sequenced DNA from 10^9 clones in naïve library (number of independently processed and deep-sequenced replicates: n=6 for ConA-selected library, n=3 for naïve, n=3 for biotin-modified naïve)

(B-C) The height of each bar is proportional to the average positional abundance of 2^{nd} (B) and 3^{rd} (C) amino acids in a population of unique sequences. Error bar is equal to one standard deviation. (C-D) The height of bars describes the same average positional abundance in a population of total sequences (each unique sequence was multiplied by its copy number). As anticipated from our selection, W and Y are abundant in 2^{nd} (B, D) and 3^{rd} (C, E) positions respectively in the ConA-selected library (blue). On the other hand, naïve non-modified and biotin-modified libraries exhibit no differences in positional abundance with one, minor exception: Leucine in position 2 is more abundant in modified library (crimson L-bar in B and D) compared to naïve library.

Figure S17. Comparison of the ligand-binding modes.

Left, superimposition of the ConA-trimannoside $(\alpha$ -Man- $(1\rightarrow 3)$ -[α -Man- $(1\rightarrow 6)$]- α -Man, orange) complex (PDB ID: 1CVN) with the present crystal structure of the glycopeptide ligand (red: Man, green: linker, blue: peptide), generated by aligning the protein backbone atoms. Right, overlay of the endogenous and synthetic ligands.

Figure S18. MD simulation of aromatic stacking between Man-WYD and ConA.

Aromatic stacking between His205 in the protein (blue) and TYR in the ligand (top), and Tyr100 in the protein (blue) and TYR in the ligand (bottom).

Table S3. List of 85 lectins printed on microarray.

Materials and general information

PBS contains 10 mM sodium phosphate dibasic, 2 mM potassium phosphate monobasic, 137 mM sodium chloride and 2.7 mM potassium chloride with pH of 7.4 after preparation. ConA from *Canavalia ensiformis* (Jack bean) was purchased from Sigma-Aldrich. ConA (2.5−10 mg, monomeric MW = 26500 Da) was dissolved in HEPES buffer $(1.0 \text{ mL}, 50 \text{ mM}$ HEPES, 150 mM NaCl, 1 mM CaCl₂, pH 7.2). After incubating for overnight at 4 °C, the ConA mixture was centrifuged for 2 min at 14000 rpm and syringe-filtered (0.22 μm). The final subunit concentration of ConA solution was determined by UV absorbance at 280 nm $(A_{280} = 1.37 \times [mg/mL \text{ ConA}])$.^{[\[5\]](#page-101-5)} LcH from *Lens culinaris* (lentil) and PSA from *Pisum sativum* (pea) were purchased from Medicago. The monomeric MW of LcH and PSA are 24500 and 23500 Da respectively.^{[\[4\]](#page-101-4)} The final subunit concentrations of LcH or PSA solution were determined by UV absorbance at 280 nm ($A_{280} = 1.26 \times$ [mg/mL LcH] or $A_{280} = 1.50 \times$ [mg/mL PSA]).^{[\[4\]](#page-101-4)} Horseradish peroxidase (HRP) was purchased from Sigma-Aldrich. All solutions used for phage work are sterilized either by autoclave or by filter sterilization $(0.22 \mu m)$

1. Solid-phase peptide synthesis

Standard Fmoc-protected amino acids, HBTU, Rink Amide AM resin, and Wang resin were purchased from ChemPrep. Poly-Prep® chromatography columns (10 mL) were purchased from Bio-Rad. Vacuum manifold was the product of Promega.

2. RP-HPLC

RP-HPLC were performed on Waters HPLC system equipped with a Waters 1525 EF binary pump, a Waters FlexInject manual injector (dual mode) and a Waters 2489 tunable UV detector. SymmetryPrepTM C18 semi-preparative column (19 \times 50 mm, particle size 5 µm, pore size 100 Å) was used for all the purification at a typical flow rate of 12 mL/min. For analytical run, Symmetry® C18 analytical column $(4.6 \times 75$ mm, particle size 3.5 µm, pore size 100 Å) was used at a typical flow rate of 1 mL/min. HPLC traces were monitored with UV detection at 220 nm and 280 nm.

3. Synthesis

2-(aminooxy)ethyl α-D-mannopyranoside was synthesized as described previously. [\[6\]](#page-101-6) *O*-α-Dmannopyranosyl oxyamine was synthesized according the literature method[.\[7\]](#page-101-7) Product purification was accomplished with automated chromatography machine (CombiFlash® Rf, Teledyne Isco, Inc.). ¹H NMR spectra were acquired on Agilent/Varian VNMRS 500 MHz and 600 MHz spectrometers in CDCl₃ (referenced to residual CHCl₃ at δ_H 7.26 ppm), CD₃OD (referenced to residual CD₂HOD at δ_H 3.3 ppm), or in D₂O (referenced to external acetone at δ_H 2.225 ppm). Chemical shift (δ) is reported in ppm and coupling constants (*J*) are given in Hz. The following abbreviations classify the multiplicity: $s = singlet, d$ $=$ doublet, t $=$ triplet, m $=$ multiplet or unresolved, br $=$ broad signal. HRMS (ESI) spectra were recorded on Agilent 6220 oaTOF mass spectrometer using either positive or negative ionization mode.

Detailed procedures for ligands search

1. Generation of Man-X7 and Me-X7 phage-displayed peptide library

N-SerX₇ phage-displayed peptide library **3** (complexity: 3×10^8 pfu) was generated according to the referred protocol.^{[\[8\]](#page-101-8)} Prior to the chemical modification, the phage library was dialyzed extensively (4 $^{\circ}$ C, 10K MWCO) against two changes of PBS (5 L) to remove the storage buffer which contains 50% (v/v) glycerol. The phage library (1 mL, \sim 4 × 10¹² pfu/mL) was oxidized with 0.06 mM sodium periodate (by adding 10 μ L of 6 mM solution in MQ water) at 4 °C for 5 min. The oxidation was quenched with 0.5 mM glutathione (by adding 10 µL of 50 mM solution in MQ water) at RT for 10 min. To monitor the oxidation, a small portion of the oxidized library was treated with aminooxy-biotin and captured with biotin-capture assay as described in a previously published method.^[6] Typically, 60% of the fractions of phage library were successfully oxidized.

The oxidized library was distributed into two separate portions of 0.75 mL and 0.25 mL, and they were treated with 1 mM 2-(aminooxy)ethyl α -D-mannopyranoside (by adding 0.75 mL of 2 mM solution in 200 mM anilinium acetate buffer, pH 4.7) and 1 mM methoxylamine (by adding 0.25 mL of 2 mM solution in 200 mM anilinium acetate buffer, pH 4.7) respectively. The reaction mixtures were incubated for 1 h at RT, after which, the excess of reagents were removed by dialysis (4 $^{\circ}$ C, 10K MWCO) against two changes of PBS (5 L) to yield the Man-X₇ library 1 and Me-X₇ library 2. To quantify the reaction efficiency, right after the oxime ligation, a small portion of the library was treated with aminooxy-biotin and captured with biotin-capture assay as described in a previously published method.^{[\[6\]](#page-101-6)} Typically, 55% of the fractions of phage library were successfully modified with the reagents.

2. Selection of chemically-modified phage library against ConA

12 wells of a 96-well polystyrene plate were coated with a solution of ConA (100 µL, 100 µg/mL) in PBS for overnight at 4 °C. These wells plus an additional three empty wells were blocked with a solution of 2% (w/v) BSA in PBS (300 μ L) for 1 h at RT. The Man-X₇ library 1 (0.9 mL), Me-X₇ library 2 (0.3 mL), and *N*-Ser-X₇ library **3** (0.3 mL) were blocked with an equal volume of $2 \times$ blocking solution (4% (w/v) BSA in PBS) for 1 h at RT. After blocking, the plate was rinsed with washing solution $(3 \times 300 \mu L, 0.1\%$ (v/v) Tween-20 in PBS) using 405^{TM} Touch Microplate Washer (BioTek). The selection of Man- X_7 library **1** against ConA (denote as screen **A**) was performed in six replicates. The control selections, i.e., Man-X₇ against BSA (**B**), Me-X₇ against ConA (**C**), and *N*-Ser-X₇ against ConA (**D**), were performed as triplicate in parallel with screen **A**. Specifically, the solutions of library **1**, **2**, or **3** were added into the corresponding wells (200 μ L/well, ~1 × 10¹¹ pfu/well). After incubating for 1 h at RT, the unbound phage was rinsed with the washing solution ($20 \times 300 \mu L$) using the plate washer. Phage remained on the well was eluted for 9 min at RT by adding 200 μ L of glycine elution buffer (0.2 M glycine-HCl, pH 2.2, 1) mg/ml BSA). The elution buffer was transferred into a 1.5-mL microcentrifuge tube and immediately neutralized with 50 µL of 1 M Tris-HCl (pH 9.1). An additional washing solution (200 µL) was added to the well to recover the remaining phage and subsequently combined with the eluate. Up to this point, the selections yielded 15 different eluates (0.45 mL per sample).

3. Phage Amplification and PCR of library DNA

The eluted phage was amplified separately by adding the eluates (15×0.45 mL) into 3 mL of ER2738 culture (1:100 dilution of overnight culture). The phage and bacterial mixtures were incubated for 4.5 h at 37 °C with vigorous shaking. The cultures were centrifuged (15 min, 4700 rpm) at 4 °C to pellet the bacterial cells. The supernatants (~3.4 mL) containing the amplified phage were poured into a fresh tube. The ssDNA of the amplified phage was extracted using QIAprep spin M13 kit (Qiagen, #27704) according to manufacturer's instructions. 15 reverse barcoded primers were designed with adapters compatible with Ion Torrent sequencing.^[9] The library DNA was subjected to PCR amplification with the barcoded primers flanking the variable region. Briefly, the library DNA (15 samples, 50 ng each) was amplified in a total volume of 50 μ L with 1× Phusion[®] buffer, 50 μ M each dNTPs, 500 μ M MgCl₂, 1 μ M forward primer, 1 µM reverse barcoded primer, and one unit Phusion® High-Fidelity DNA Polymerase. PCR was performed using the following thermo cycler program: a) 98 °C 30 s, b) 98 °C 10 s, c) 60 °C 20 s, d) 72 °C 30 s, e) repeat b)−d) for 34 cycles (total 35 cycles), f) 72 °C 5 min, g) 4 °C hold. The dsDNA fragments from the PCR were quantified by running at 2% (w/v) agarose gel in Tris-Borate-EDTA buffer at 100 volts for ~45 min using a low molecular weight DNA ladder as a standard (NEB, #N3233S). The dsDNA fragments (15 samples, 40 ng per sample) were pooled together and purified on E-Gel® SizeSelectTM 2% agarose gel (Invitrogen, #G6610-02). The desired band corresponding to 121 bp with reference to the ladder was collected with RNAse-free water and the concentration was determined by Qubit® Fluorimeter (Invitrogen, #Q32851) using manufacturer's protocol.

4. DNA template preparation and Ion Torrent sequencing

Ion PGM™ Template OT2 200 Kit (Life Technologies) was used to prepare the DNA template for sequencing. Briefly, the pooled and purified dsDNA fragments were hybridized onto Ion Sphere Particles (ISPs) and amplified by emulsion PCR using Ion OneTouch™ 2 System according to manufacturer's protocol. The fraction of ISPs loaded with the DNA template was determined with Qubit® Fluorimeter (Invitrogen) according to manufacturer's protocol. The ISPs loaded with the DNA template were enriched and deposited in Ion 316^{TM} chip. The DNA sequencing was performed on Ion PGMTM System using Ion PGM[™] Sequencing 200 Kit v2. The FASTQ file generated from the sequencing data was processed by in-house MATLAB script that identified the barcodes and constant flanking regions, and extracted the reads of the correct length (24 bp only) corresponding to the $TCT(NNK)₇$ structure.

5. Volcano plot and generation of sequence logos

This plot identified sequences isolated from **A** screen that increased significantly in abundance against sequences isolated from the control selection. The copy number of each sequence is normalized through dividing the copy number by the total number of reads in each replicate. Sequences not observed in a specific replicate were assigned a copy number of zero. For volcano analysis, the ratio of each sequence was calculated through dividing the mean fraction of the particular sequence in **A** screen by that in the control screen (e.g., **B**, **C**, or **D**). Since the denominator must not be a zero when taking the ratio, sequences with zero copy number found in all three replicates are assigned with 0.3 copy number before taking the normalization. Significance of the ratio was assessed using one-tailed, unequal variance Student *t*-test. The ratio is considered to be statistically significant if the calculated *p*-value ≤ 0.05 . Only sequences with ratio ≥ 5 and *p*-value ≤ 0.05 were included in the set $\bf{A/B}, \bf{A/C},$ and $\bf{A/D}$. The volcano plot was generated using in-house MATLAB script. Sequence LOGO was generated using the MATLAB function *seqlogo* with *StartatValue* set as 2 and *EndatValue* set as 8 (define the range of position to be considered in the sequence).^{[\[10\]](#page-101-10)}

Affinity maturation from Man-WY[D/E]X₇ library

1. Generation of N-SerWY[D/E]X7 phage-displayed peptide library

Library preparation was adapted from *Noren et al.*^{[\[8\]](#page-101-8)} with minor modifications. An oligonucleotide library was designed to code for the amino acid sequence SWY[D/E], followed by a 7-mer variable region (NNK) ₇ and GGG linker. The oligonucleotide also includes a KpnI restriction enzyme recognition site (underlined) at the 5' end, followed by the pIII leader sequence of phage M13KE and a fixed Ser. At the 3' end, there is an EagI site (underlined). The oligo sequence corresponding to the **anti-sense** strand is as follows:

3'-GGGCCCATGGAAAGATAAGAGTGAGAAGAACCATGCTN(NNM)7CCACCTCCAAGCCGGCCCGCG-5'

S W Y D/E X_7 G G G

where $K = G$ or T, $M = A$ or C, and $N = G$, T, A, or C.

In a 0.2-mL PCR tube, 200 pmoles of single-stranded oligonucleotide library and 3 molar equivalents of extension primer (5'- CATGCCCGGGTACCTTTCTATTCTC-3') were combined in 100 mM NaCl to a final volume of 50 μL. In a thermal cycler, fragments were annealed using a program that begins with an initial temperature of 95 \degree C and cools to 4 \degree C over 90 min. Extension of the annealed duplex was achieved by adding 20 μL of Klenow fragment reaction buffer, 50 μM dNTPs (final concentration), 15 U Klenow fragment (#EP0051, Thermo Scientific) and DNase-free water to a 1.5-mL microcentrifuge tube, to a final volume of 150 μL. The reaction mixture was incubated for 15 min at 37 °C. The extended library oligonucleotide was purified by ethanol precipitation by adding 20 μL of 3 M sodium acetate, 400 μL of 100% ethanol and 1 μL glycogen. The mixture was incubated for 2 h at -20 °C and centrifuged at 14,000 rpm for 10 min at 4 °C, followed by a washing step using 500 μL of 70% ethanol and a final centrifugation step at 14,000 rpm for 10 min at 4 °C. The sample was re-suspended in 25 μL DNase-free water or TE buffer. The digestion of the library duplex was performed using KpnI and EagI FastDigest restriction enzymes (#FD0524 and #FD0334, Thermo Scientific) and the reaction was set up according to manufacturer instructions. A 2% E-Gel® SizeSelect[™] Gel was used to purify oligonucleotide digests. M13KE vector was also digested using KpnI and EagI FastDigest enzymes as per manufacturer instructions and purified by 0.7% agarose gel extraction. For the ligation step, 50 ng of M13KE cut vector and library duplex were combined at a molar ratio of 1:30 in a 0.2-mL PCR tube with 1 μL of 400 U T4 DNA Ligase, 2 μL of 10× Ligase Buffer and DNase-free water to a final volume of 20 μL and incubated overnight at 16 °C. Transformation of bacterial cells was performed by electroporation of ethanol precipitation purified DNA (see above) into TG1 electrocompetent cells (Lucigen) according to manufacturer's specifications. After transformation, cells were incubated at 37 °C for 45 min to generate the inoculating culture that was added to 25 mL of LB media and further amplified at 37 °C for 4.5 h. Viral particles were collected by PEG/NaCl precipitation from supernatant of culture, titered and stored in PBS and 50% glycerol for further experiments.

2. Modification, panning and sequencing

The modification of the library was exactly the same as described above. 50% of the fractions of phage library were successfully modified with 2-(aminooxy)ethyl α-D-mannopyranoside. Both modified and non-modified libraries were subjected to affinity selection using the procedure as described above. After the elution of bound phage, it was amplified and subjected to a second round of modification and affinity selection. Eventually, the isolated phage DNA was obtained and sequenced by Ion Torrent. The same analysis was applied to narrow down the hits.

Surface plasmon resonance (SPR)

Buffer was sterile-filtered before use. All ligands were pre-dissolved in a 5% volume of DMF followed by the addition of HEPES buffer (50 mM HEPES, 150 mM NaCl, 1 mM CaCl₂, pH 7.2). Solution of ConA tetramer (0.4 mg/mL) was prepared using the same buffer. The measurements were recorded on BIAcore 2000 instrument using CM5 chip (carboxylated dextran) as the binding target for ConA. To perform the competitive inhibition, ConA (0.4 mg/mL) was mixed with an equal volume of inhibitor and this mixture (50 μ L) was injected (10 μ L/min). Inhibitor concentrations of 0, 0.0001, 0.0003, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1 mM were tested. Two more data points (3 and 10 mM) were included for inhibition with MeMan. The solution of inhibitor in the absence of ConA was injected each time before the injection of the ConA/inhibitor mixture of the same concentration. The response values were used for subtraction to account for the bulk effect caused by the inhibitor itself. The chip was regenerated after each injection with the regeneration buffer (6 M guanidinium chloride). Bound ConA response values were assessed during the equilibrium binding portion of the curve (280 s after injection). The corrected response value (R_{max}) of bound ConA in the absence of inhibitor was set as 0% inhibition. The degree of inhibition by the inhibitor was calculated with the equation $R_{\text{max}}-R_{\text{inh}}/R_{\text{max}}$, where R_{inh} is the corrected response value given by the bound ConA in the presence of certain concentration of inhibitor.

Isothermal titration calorimetry (ITC)

ITC were performed using a Microcal VP-ITC instrument. Ligands were pre-dissolved in a small amount of DMF followed by the addition of HEPES buffer (50 mM HEPES, 150 mM NaCl, 1 mM CaCl₂, pH 7.2). The final solvent was HEPES buffer containing 2% (v/v) DMF. In the case, where ligands have poor solubility in the prepared buffer, up to 5% (v/v) DMF was used. The ConA solution was prepared with the same buffer as the ligand. All solutions were degassed with MicroCal ThermoVac unit prior to use. All titrations were carried out at 30 °C. An initial injection of 2 µL followed by a total of 41 injections of ligand solution (7 μ L) were added at intervals of 4 min into the solution of ConA (cell volume = 1.44 mL) while stirring at 300 rpm. Typically, the initial concentrations of ConA and ligands were 0.05−0.30 mM and 2 mM respectively, unless otherwise specified. The quantity $c = K_a M$, where M is the initial macromolecule concentration, is of importance in ITC. All experiments were performed with *c* values in the range of $1 < c < 100$, except for the ligands with $K_a \le 1000 \text{ M}^{\text{-}1}$, where preparation of ConA with concentration > 1 mM is difficult due to solubility issue. In the case where heat of dilution is significant, titration data obtained by making identical injection of ligand into the buffer without ConA was subtracted from the titration data obtained in the presence of ConA. The data point produced by the first injection was discarded prior to curve fitting in order to account for the diffusion effect during the equilibration process. The experimental data were fitted to a non-interacting one-site binding model using Origin software supplied by Microcal, with ΔH (enthalpy change), *K*^a (association constant) and n (number of binding sites per monomer) as adjustable parameters. Free energy change (ΔG) and entropy contributions (T ΔS) were determined from the standard equation: $\Delta G = \Delta H - T \Delta S = -RT \ln K_a$, where T is the absolute temperature and $R = 1.987$ cal mol⁻¹ K⁻¹.

For ITC measurements of ligand binding to LcH or PSA, exactly the same protocol was used as described above.

Protein Crystallization

Jack bean concanavalin A, type V, used for crystallization trials, was purchased from Sigma-Aldrich, St. Louis, Missouri, USA. Prior to crystallization, a sample of ConA (20 mg/mL) in 1 M NaCl, 50 mM NaOAc at pH 5.0, 1 mM CaCl₂, 1 mM MnCl₂ was incubated at 42 °C for 2 hours and dialyzed against three changes of 0.1 M NaCl, 20 mM Tris pH 7, 1 mM $CaCl₂$, 1 mM $MnCl₂$. For crystallization trials, ConA was concentrated to 14-15 mg/mL. About 1 hour prior to crystallization the solution of ConA was combined with the stock solution of Man-WYD in DMSO at a molar ratio of 1:10 (ConA : ligand). Initial crystals were obtained from QIAGEN's the JCSG Core II Suite, condition #34: 0.1 M HEPES pH 6.5, 10 % (w/v) PEG 6000. Diffraction quality co-crystals were grown at 20 °C in sitting drop microbridges using well solutions consisting of 0.1 M HEPES pH 6.5 and 10-16 % PEG 6000.

X-ray Data collection

Prior to data collection crystals were placed in a cryoprotectant solution composed of 75% well solution and 25% glycerol and then flash cooled by immersion in liquid nitrogen. X-ray diffraction data were collected at 100K over a range of 100° (1° steps) using an ADSC Quantum 315r detector at the Advanced Photon Source (APS) on the ID19 beamline SBC-CAT to 1.73 Å resolution. Reduction of the X-ray data was performed using the $XDS^{[11]}$ $XDS^{[11]}$ $XDS^{[11]}$ and the CCP4 suite.^{[\[12\]](#page-101-12)} Refinement was completed using the *phenix.refine* program in the *PHENIX* suite^[13] and the resulting structure analyzed with molprobity.^{[\[14\]](#page-101-14)}

X-ray data collection (110K)

MD analysis

Comparison of the ligand-binding mode

A crystal structure of the ConA protein bound to trimannoside (PDB ID: 1CVN) has been reported at 2.3 Å resolution. The mannopyranosyl (Man) residue of the synthetic ligand used in the present study and Man-240 (the 1,6-linked Man) in the endogenous ligand, bind to the protein at the same site (Figure 3B) and in the same ${}^{4}C_{1}$ conformation (Figure S17). These two Man residues displayed equivalent hydrogenbonding patterns (Arg228 NH to O3, Asn14 side chain NH to O4, Leu99 NH to O5, and Tyr100 NH to O6). In contrast to the endogenous trimannoside, the synthetic ligand forms few additional hydrogen bonds, and prefers to van der Waals contacts with the protein surface (Figure S7). This is as shown by a higher contact area of synthetic ligand (662 Å) compared to the trisaccharide Man3 (204 Å).

A number of structural studies show that a conserved water molecule plays an important role in facilitating the ConA-carbohydrate interaction, by forming hydrogen bonds with ARG 228, ASP 16, ASP 14 and MAN 241.^[15] A crystallized water molecule is present at the same location in the present protein structure, but because of the absence of MAN 241 in the synthetic ligand, this water does not mediate hydrogen bond formation with the ligand.

To examine the stabilities and strengths of these interactions, and to study the dynamics of the ligand in the binding pocket of the protein, a 50 ns molecular dynamics (MD) simulation was performed with the AMBER/GLYCAM force field and explicit water. The ligand-protein complex remained stable over the course of the simulation (average backbone RMSD = 0.69 (0.03) Å, average ligand displacement RMSD $= 1.62$ (0.32) Å).

Key interactions between protein and ligand

1. Hydrogen bonds

The MAN residue forms two stable hydrogen bonds with ASN 14 and ASP 208. TYR in the ligand also participates in the hydrogen bonding with PRO 206. The bonds with ASP 208 and PRO 206 are not present in the crystal structure, whereas the hydrogen bonds of MAN with LEU 100, ARG 228 and TYR 100, which exist in the crystal structure, are not formed during the MD simulation.

Donor		Acceptor					
Residue	Atom	Residue	Atom	MD Occupancy ^[b]	MD Distance ^[c]	X -ray	
MAN	O4	ASN 14	$N\delta2$	100	2.9(0.1)	2.98	
ASP 208	$O\delta2$	MAN	O4	100	2.6(0.1)	2.52	
PRO 206	O	TYR (ligand) OH		100	2.7(0.1)	2.45	
MAN	O ₃	ARG 228	N	100	3.0(0.1)	2.88	
MAN	O ₆	TYR 100	N	99	3.1(0.1)	3.22	
MAN	O5	LEU ₉₉	N	97	3.2(0.2)	2.93	

Table S4. Intermolecular hydrogen bonds^[a] between protein and ligand

 $^{[a]}$ Based on a distance cut-off of 3.5Å.

^[b] In percent of total simulation.

[c] Average distance in Å.

2. Hydrophobic interactions

HIS 205 in the protein interacts with TYR in the ligand via parallel displaced aromatic stacking. The histidine ring flips through the simulation maintaining this interaction, but it might not be strong enough to prevent it from flipping. TYR 100 in the protein also interacts with TYR in the ligand via CH/π interaction. This interaction can provide binding energy of 3.54 kcal/mol, as estimated by QM calculation at MP2/aug-cc-pVQZ, between two benzene rings in this conformation.^[16] These interactions were characterized by the angle (θ) between the normals to the ring planes, and the distance (R) between their centroids (Figure S18).^[17] For a stacking conformation, θ should be around 180° or 0°, and for CH/ π , it should be around 90°. In case of HIS 205 the average θ over the flipped and non-flipped arrangement is 138° and 21° at an average distance of 4.8 Å, while with TYR 100, the average θ is 93° at 5.1 Å.

Binding free energy analysis

The results from the binding free energy analysis were sorted and ranked on the basis of the per-residue total energy contributions (see Figure S8 and Table S2). Using this information, the residues significant to the ligand binding were identified. Residues involved in hydrogen bonds and hydrophobic interactions are amongst the top contributors, and stabilize the binding mainly via electrostatic and van der Waals interactions respectively. TYR 100 was involved in a hydrogen bond with the ligand in the crystal structure, but that bond does not exist during the simulation and largely its contribution to binding is through van der Waals. Most of the high ranked residues are hydrophobic which suggests that the binding interaction could mainly be non-polar. With regard to the ligand, the Man residue appears to contribute over 50% of the interaction energy, with the remainder coming principally from the TYR and TRP residues.
Method for MD simulation

1. Preparation of protein and ligand structures

Antechamber was used to develop GAFF charges and force field parameters for the linker; ff12SB^[18] parameters were employed for the amino acids and GLYCAM06j parameters for the sugar (see Figure below). The complex was solvated in a truncated octahedral box of 9837 TIP3P water molecules with counter ions (Na⁺) added to neutralize the charge, using the tLEAP module of AMBER. All histidine residues were considered neutral with hydrogen at the ε-position. The crystalized water molecules were retained and appropriate hydrogen atoms were added using a tool provided by AMBERTOOLS called protonator.

Figure. Components of the ligand colored according to the source of the force field parameters: GLYCAM06j (red), GAFF (green), and AMBER12SB (blue).

2. Energy Minimization

All simulations were performed with a cutoff for non-bonded interactions of 10 Å. To remove bad contacts, the system was minimized in two steps. Firstly, the energy of the water and ions was minimized while keeping all protein atoms restrained (500 kcal/mol \AA^2). This was followed by energy minimization of the entire system. Each minimization was comprised of an initial phase of steepest descent method for 5000 steps, followed by conjugate gradient for 20000 steps using AMBER12. The resulting minimized structure was subjected to MD simulation performed with the pmemd.cuda version of AMBER12.^{[\[19\]](#page-101-1)}

3. MD Simulation

All the bonds involving hydrogen were constrained using the SHAKE algorithm,^{[\[20\]](#page-101-2)} enabling an integration time step of 2 fs. Long-range electrostatic interactions were treated with the Particle-Mesh Ewald algorithm.^{[\[21\]](#page-101-3)} The systems were heated from 5 K to 300 K over a span of 50 ps, under nVT conditions employing the Langevin thermostat using a collision frequency of 1.0 ps^{-1} . The simulation was then continued for 50 ns under nPT conditions with weak restraints on the backbone atoms (10 kcal/mol \AA^2).

4. Data Analysis

Ligand contact areas were computed with NACCESS.^{[\[22\]](#page-101-4)} Binding free energies were calculated using single trajectory Molecular Mechanics-Generalized Born Solvation Area (MM-GBSA) method, and the solvation energies were approximated with an implicit solvent $(igb=2)$.^{[\[23\]](#page-101-5)} For this analysis all the water

molecules and ions were removed from the complex, and average energy values were computed over an ensemble of 5000 snapshots, collected every 10 ps from MD trajectory. The MM-GBSA energy was decomposed to obtain per-residue contribution, in terms of van der Waals and electrostatic energies, and nonpolar and polar solvation free energies, and the residues were sorted on the basis of mean total energy binding contribution.

1D STD-NMR experiments

The experiments were conducted on Agilent/Varian VNMRS 600 MHz spectrometer at a probe temperature of 300 K. The NMR samples were prepared by pre-dissolving the ligand in a small amount of DMSO- d_6 (14 µL), followed by the addition of ConA in deuterated PBS (686 µL). Deuterated PBS was prepared from $1 \times PBS$ (pH 7.4) by two cycles of lyophilization and redissolution in D₂O. The final samples contained ligand/ConA in a ratio of 40:1 (2 mM ligand, 0.05 mM ConA). The NMR experiments involved the selective saturation of protein resonances at 0.2 ppm (30 ppm for reference spectra) using a cascade of 20 Gaussian-shaped pulses (50-ms duration, 1-ms delay between each pulse) resulting in a total saturation time of 1.02 s. WATERGATE W5 sequence^[2] was used to suppress the residual HDO signal. A 30-ms *T*1^ρ filter was applied to suppress protein background. STD-NMR spectra were obtained by subtracting the saturated spectra from the reference spectra *via* phase cycling. The integral regions of the reference spectra were copied to the STD-NMR spectra to guarantee identical boundaries and unbiased ratio of the particular integrals. Relative STD effects were calculated according to the equation $E_{\text{STD}} = (I_0 - I_{\text{sat}})/I_0 = I_{\text{STD}}/I_0$ by comparing the intensity of the signals in the STD-NMR spectrum (I_{STD}) with intensity of the signals in a reference spectrum (I_0) . Control STD experiments using the free ligand (Man-WYD) were performed under the same experimental conditions to verify true ligand binding. No signal was present in the STD-NMR spectra, indicating that the effects observed in the presence of the protein were due to true saturation transfer with negligible artifacts. The reference spectra and STD-NMR spectra of Man-WYD and Man-NL-WYD were shown at the following page.

Black traces: STD-NMR spectra

Lectin microarray printing and analysis

Lectin arrays were printed according to the method described in literature.^{[\[24\]](#page-101-7)} Briefly, lectins were printed using Nano-Plotter non-contact piezoelectric printer at 100 volts onto Nexterion H slides at 45% humidity and 13˚C. For a printlist see Table S3. Slides were blocked with 25 mM ethanolamine in 100 mM sodium borate (pH 8.0) for one hour with gentle rocking. Man-WYK-OH labeled with Cy3 were diluted by serial dilutions (3.33µM, 2.50µM, 1.88µM, 1.41µM, and 1.05µM, 100 µL total volume) in nano-pure water and then analyzed as previously described.^{[\[24\]](#page-101-7)} In brief, samples were incubated on the arrays for two hours followed by five washes with $0.1 M NaH₂PO₄$, $0.15 M NaCl$, $0.01%$ Tween 20 (pH 7.2). The slides were dried by spinning and scanned using GenePix 4300a slide scanner at PMT of 450 at 532nm with 100% power. Signals were tested for outliers by Grubbs tests (critical value of 1.15). Data was subjected to Zscore transformation^[25] and a significance cutoff of $Z=1.95$ ($p < 0.01$) was applied to look for significant signals.

ESI-MS binding measurement

1. Sample preparation

Monomeric carbohydrate-recognition domain of dendritic cell-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN, MW 17 802 Da) was a gift from Professor Kurt Drickamer (Imperial College, London). Chicken egg white lysozyme (Lyz, MW 14 315 Da) was purchased from Sigma-Aldrich Canada (Oakville, ON, Canada). Protein stock solutions were prepared by exchanging protein into 100 mM ammonium acetate using Vivaspin 500 centrifugal concentrators with a 10 kDa MW cut-off (Sartorius Steddin Biotech, Gottingen, Germany). The protein concentrations were measured using Pierce[™] BCA Protein Assay Kit. The ESI solutions containing 8.5 µM DC-SIGN, 5 µM Lyz, 50 µM Man-WYD (**L20**) or Man-NL-WYD (**L20.3**) and 10 mM ammonium acetate were prepared from the stock solutions. Lyz was added to the ESI solutions to act as a reference protein,^{[\[26\]](#page-101-9)} so that nonspecific binding during the ESI process could be corrected.

2. Mass spectrometry

Binding measurements were performed on a Synapt G2-S quadrupole-ion mobility separation-time-offlight (Q-IMS-TOF) mass spectrometer (Waters UK Ltd., Manchester, UK) equipped with a nanoflow ESI source. ESI was performed using nanoESI tips pulled from borosilicate glass capillaries (1.0 mm o.d., 0.78 mm i.d.) using a P-97 micropipette puller (Sutter Instruments, Novato, CA, USA). Mass spectra were obtained in positive ion mode using cesium iodide (concentration 30 ng μL^{-1}) for calibration. A capillary voltage of 1.1 kV under positive mode was applied to carry out nanoESI. A cone voltage of 30 V was used and the source block temperature was maintained at 80 °C. Other important voltages for ion transmission, that is the injection voltages into the trap and transfer ion guides, were maintained at 5 and 2 V, respectively. Argon was used in the trap and transfer ion guides at a pressure of 2.22×10^{-2} mbar and 3.36×10^{-2} mbar, respectively. Data acquisition and processing were carried out using MassLynx (ver. 4.1).

Inhibition studies of ConA and DC-SIGN by competitive binding assay

Tetrameric extracellular domain of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) was a gift from Professor Kurt Drickamer (Imperial College, London). The competitive binding assay involves the binding of immobilized lectins, i.e., ConA or DC-SIGN, to horseradish peroxidase (HRP), a glycoprotein containing trimannoside epitope, under the competition of the studied inhibitors, i.e., MeMan, Man-WYDLF, or Man3-X. Buffer used in the experiment was a solution of 50 mM MOPS, 150 mM NaCl, and $2mM$ CaCl₂ (pH 7.4). A solution of ConA or DC-SIGN (10 µg/mL) dissolved in the buffer was used to coat a polystyrene plate (Costar #3369) to have a final volume of 50 µL/well. The plate was sealed with a membrane and kept in fridge for overnight. In a separate non-binding surface plate (Corning #3641), a 3-fold serial dilution was performed for the solutions of the inhibitor dissolved in the buffer. The diluted solutions were then mixed with an equal volume of the solution of HRP (2 µg/mL) dissolved in the same buffer. The coating solution of lectin was aspirated using 405™ Touch Microplate Washer (BioTek) and subsequently washed with the washing solution (10 \times 300 µL, the same buffer containing 0.1% (v/v) Tween-20). The mixture of the inhibitor and HRP probe was transferred accordingly onto the plate coated with the lectin to have a final volume of 50 µL/well. The plate was incubated at RT for 1 h. Then, the plate was washed with the washing solution (10 \times 300 µL) and the TMB substrate (50 µL) was added to each well. After 5 min incubation for ConAcoated well or 10 min incubation for DC-SIGN-coated well, 1 M phosphoric acid (50 µL) was added to quench the colorimetric assay. The color developed was read at 450 nm with 96-wells plate reader. The data was fitted with logistic function using Origin software to determine the half maximal inhibitory concentration (IC_{50}) of the studied inhibitor.

Synthesis of carboxymethylthiopropyl α**-D-mannopyranoside**

*1. Methoxycarbonylmethylthiopropyl 2,3,4,6-tetra-O-acetyl-*α*-D-mannopyranoside*

A solution of allyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (900 mg, 2.3 mmol) and methyl thioglycolate (0.31 mL, 1.5 eq.) in CH_2Cl_2 (20 mL) was irradiated with UV lamp at 254 nm for 1 h then concentrated. Chromatograpy of the residue on silica gel in CH_2Cl_2 -MeOH (50:50) gave the title compound (980 mg, 85%): ¹H NMR (500 MHz, CDCl₃) δ = 5.35 (dd, 1 H, *J*_{2,3} = 3.3 Hz, *J*_{3,4} 9.8 Hz, H-3), 5.29 (t, 1 H, H-4), 5.26 (dd, 1H, $J_{1,2} = 1.7$ Hz, H-2), 4.84 (d, 1 H, H-1), 4.30 (dd, 1 H, $J_{6a,6b} = 12.2$, $J_{5,6a} =$ 5.2 Hz, H-6a), 4.14 (dd, 1H, $J_{5,6b} = 2.20$ Hz, H-6b), 3.97 - 4.04 (m, 1 H, H-5), 3.84 (dt, 1 H, $J = 9.8$, $J =$ 6.3 Hz, CH2), 3.77 (s, 3 H, OMe), 3.57 (dt, 1 H, *J* = 9.8, *J* = 6.0 Hz, CH2), 3.26 (s, 2 H, CH2), 2.75 (t, 2 H, CH2S), 2.18 (s, 3 H, OAc), 2.13 (s, 3 H, OAc), 2.07 (s, 3 H, OAc), 2.01 (s, 3 H, OAc), 1.95 (dq, *J* = 13.39, $J = 6.97$ Hz, 2 H, CH₂). ¹³C NMR (125 MHz, CDCl₃) $\delta = 170.79$ (CO), 170.64 (CO), 170.04 (CO), 169.86 (CO), 169.71(CO), 97.64 (C-1), 69.58 (C-2), 69.09 (C-5), 68.61 (C-3), 66.43 (CH₂), 66.18 $(C-4)$, 62.49 $(C-6)$, 52.41 (OMe), 33.38 (CH_2) , 29.28 (CH_2) , 28.50 (CH_2) , 20.89 (OAc), 20.76 (OAc), 20.71 (OAc), 20.69 (OAc).

2. Carboxymethylthiopropyl α*-D-mannopyranoside*

To a solution of above compound (800 mg, 1.62 mmol) in dry MeOH (5 mL), 1 M NaOMe (1 mL) was added. After 1 h incubation, the mixture was concentrated, taken up in water (5 mL), and 2 M NaOH (1 mL) was added. After overnight incubation the mixture was treated with Dowex (H⁺) and filtered. The supernatant was freeze-dried. Chromatography of the residue on silica gel in CH_2Cl_2 -MeOH (50-100%) afforded the title compound (355 mg, 67%): ¹H NMR (498 MHz, D₂O) δ = 4.82 (d, 1 H, *J*_{1,2} = 1.5 Hz, H-1), 3.90 (dd, 1 H, *J*2,3 = 3.3, H-2), 3.87-3.54 (m, 7 H, H-3, H-4, H-5, H-6a, H-6b, CH2), 3.36 (s, 2 H, CH₂), 2.65 - 2.75 (m, 2 H, CH₂), 1.82 - 1.95 (m, 2 H, CH₂). ¹³C NMR (126 MHz, D₂O) δ = 175.00 (CO), 99.77 (C-1), 72.80, 70.62, 70.10, 66.76, 66.04 (CH₂), 60.93 (C-6), 33.39 (CH₂), 28.75 (CH₂), 28.07 $(CH₂).$

Synthesis of Man3-X (X = 6-azidohexyl)

*6-Azidohexyl O-(2,3,4,6-tetra-O-acetyl-*α*-D-mannopyranosyl)-(1*→*6)-[(2,3,4,6-tetra-O-acetyl-*α*-Dmannopyranosyl)-(1*→*3)]-2,4-di-O-benzoyl-*α*-D-mannopyranoside (3)*

A mixture of diol **2** (102 mg, 0.20 mmol), imidate **1** (315 mg, 0.64 mmol) and 4 Å molecular sieves (0.4 g) in anhydrous dichloromethane (4 mL) was stirred for 2 hours under argon. The mixture was cooled to 0 $^{\circ}$ C and BF₃. Et₂O (60 µL, 0.47 mmol) was added drop wise. The reaction mixture was allowed to warm up to room temperature slowly and stirred overnight. Triethylamine (0.7 mL) was added, and the solid was filtered off and the obtained solution was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using a gradient of ethyl acetate – hexane ($10\rightarrow 35\%$) as the eluent to yield compound 3 as a colorless foam (133 mg, 57% yield). $[\alpha]_D^{25}$: + 5.8 (*c* 0.43, CHCl₃). ¹H NMR (400 MHz, CDCl₃) $\delta = 8.17 - 8.11$ (m, 2H, Bz), $8.07 - 8.02$ (m, 2H, Bz), $7.65 - 7.51$ (m, 4H, Bz), 7.45 (m, 2H, Bz), 5.61 (dd, *J* = 10.0, 10.0 Hz, 1H, H-4_Man_B), 5.49 (dd, *J* = 3.4, 1.7 Hz, 1H, H-2_Man_B), 5.33 (dd, *J* = 10.1, 3.4 Hz, 1H, H-3_Man_C), 5.28 – 5.19 (m, 2H, H-2_Man_C + H-4_Man_C), 5.14 – 5.05 (m, 2H, H-3_Man_A + H-4_Man_A), 5.03 - 4.99 (m, 2H, H-1_Man_A + H-1_Man_B), 4.87 (dd, *J* = 2.9, 2.0 Hz, 1H, H-2_Man_A), 4.79 (d, *J* = 1.6 Hz, 1H, H-1_Man_C), 4.45 (dd, $J = 9.7, 3.4$ Hz, 1H, H-3 Man B), $4.22 - 3.94$ (m, 7H, H-5 Man A + H-5 Man B + H-5 Man C + H-6a_Man_A + H-6b_Man_A + H-6a_Man_C + H-6b_Man_C), 3.90 (dd, *J* = 10.7, 7.1 Hz, 1H, H-6a_Man_B), 3.79 (ddd, *J* = 9.7, 9.7, 6.7 Hz, 1H, OC*H*aHbCH2), 3.59 (dd, *J* = 10.6, 1.9 Hz, 1H, H-6b_Man_B), 3.53 (ddd, *J* = 9.7, 9.7, 6.4 Hz, 1H, OCHa*H*bCH2), 3.30 (t, *J* = 6.9 Hz, 2H, CH2N3), 2.11 (s, 3H, Ac), 2.11 (s, 3H, Ac), 2.04 (s, 3H, Ac), 1.97 (s, 3H, Ac), 1.94 (s, 3H, Ac), 1.90 (s, 3H, Ac), 1.87 (s, 3H, Ac), 1.82 (s, 3H, Ac), 1.75 – 1.59 (m, 4H, OCHaHbC H_2 + C H_2 CH₂N₃), 1.51 – 1.38 (m, 4H,

 $CH_2CH_2CH_2CH_2N_3)$. ¹³C NMR (100 MHz, CDCl₃) $\delta = 170.56$ (CO), 169.91 (CO), 169.73 (CO), 169.69 (CO), 169.50 (CO), 169.19 (CO), 169.05 (CO), 166.00 (CO), 165.33 (CO), 133.63, 133.57, 129.97, 129.89, 129.14, 128.78, 128.51 (Bz), 99.55 (C-1_Man_B), 97.16 (C-1_Man_A), 97.13 (C-1_Man_C), 75.97 (C-3_Man_B), 71.92 (C-2_Man_B), 69.42, 69.36, 69.29, 69.25, 68.90, 68.67, 68.53, 68.26, 68.12 (O*C*HaHb), 66.66 (C-6_Man_B), 65.90, 65.88 (C-4_Man_A, C-4_Man_C), 62.27, 62.13 (C-6_Man_A, C-6_Man_C), 51.32 (CH₂N₃), 29.21 (CH₂), 28.73 (CH₂), 26.49 (CH₂), 25.70 (CH₂), 20.82 (Ac), 20.71 (Ac), 20.64 (2 × Ac), 20.59 (Ac), 20.56 (Ac), 20.45 (2 × Ac). HRMS m/z calc'd for $C_{54}H_{71}N_4O_{26}Na$ (M+NH₄⁺): 1191.4357; found: 1191.4316.

*6-Azidohexyl O-(*α*-D-mannopyranosyl)-(1*→*6)-[(*α*-D-mannopyranosyl)-(1*→*3)]-*α*-Dmannopyranoside (4, Man3-X)*

Compound **4** (100 mg) was dissolved in anhydrous methanol (10 mL), and a 1.5 M solution of NaOMe in MeOH (0.5 mL) was added. The mixture was stirred at room temperature for 3 hrs. The solution was neutralized with Amberlite IR-120 (H⁺) resin, and evaporated under reduced pressure. The residue was dissolved in deionized H_2O , purified by HPLC on a reverse phase C18-bond silica gel column using a gradient of MeOH - H₂O (0 \rightarrow 40%) as the eluent. The desired trisaccharide 4 was obtained as a fluffy colorless solid after freeze-drying (48.0 mg, 90% yield). $[\alpha]_D^{25}$: + 96.5 (*c* 0.49, H₂O). ¹H NMR (600 MHz, D2O) δ = 5.13 (d, *J* = 1.6 Hz, 1H), 4.92 (d, *J* = 1.6 Hz, 1H), 4.85 (d, *J* = 1.6 Hz, 1H), 4.11 (dd, *J* = 2.1, 2.1 Hz, 1H), 4.09 (dd, *J* = 3.4, 1.7 Hz, 1H), 4.04 – 3.99 (m, 2H), 3.94 – 3.87(m, 5H), 3.87 – 3.82 (m, 2H), 3.81 – 3.65 (m, 9H), 3.59 (ddd, *J* = 9.9, 9.9, 6.0 Hz, 1H), 3.36 (t, *J* = 6.6 Hz, 2H), 1.72 – 1.59 (m, 4H), $1.49 - 1.37$ (m, 4H). ¹³C NMR (150 MHz, D₂O) $\delta = 102.34$, 99.85, 99.35, 78.55, 73.30, 72.66, 71.02, 70.60, 70.32, 70.02, 69.95, 69.68, 67.94, 66.75, 66.70, 65.74, 65.29, 61.02, 60.92, 51.10, 28.34, 27.88, 25.63, 24.97. HRMS m/z calc'd for $C_{24}H_{43}N_3O_{16}Na (M+Na^+)$: 652.2541; found: 652.2522

Synthesis of Man-peptide conjugates

1. Solid-phase peptide synthesis

The procedure of peptide synthesis was adapted from the literature.^[27] Briefly, Rink Amide AM resin (200 mg, 0.91 mmol g^{-1} , 0.18 mmol) was weighed into a Poly-Prep® chromatography column. The column was set up on a vacuum manifold. The manifold was equipped with a three-way stopcock that allows draining of the solvent by vacuum filtration and agitation of the resin by nitrogen bubbling.^{[\[28\]](#page-101-11)} $CH₂Cl₂$ (3 mL) was added to the dried resin for swelling. After 15 min, the solvent was drained by vacuum filtration. The resin was washed with DMF (3 mL) and then deprotected with 20% (v/v) piperidine in DMF (3 mL) for 1 min. The deprotection was repeated for another 10 min using fresh 20% (v/v) piperidine in DMF (3 mL). The resin was washed with DMF (4 \times 3 mL). Fmoc-protected amino acid (0.73 mmol, 4 eq.) and HBTU (276 mg, 0.73 mmol, 4 eq.) dissolved in DMF (3 mL) were added to the resin. After 30 s agitation, DIPEA (0.25 mL, 1.46 mmol, 8 eq.) was added to the mixture. After 30 min agitation, the reagents were removed by vacuum filtration and the resin was washed with DMF (4×3) mL). The Fmoc-deprotection, amide coupling, and washing steps were repeated consecutively to elongate the sequence up to Fmoc-Ser(tBu)-OH, the *N*-terminal residue. After Fmoc-deprotection, the resin was washed with DMF (5 \times 3 mL), followed by CH₂Cl₂ (5 \times 3 mL). The resin was left on the manifold for 10 min to dry under the vacuum. A cleavage cocktail (2 mL) containing TFA/H₂O/phenol/TIPS [85/5/5/5] $(v/v/w/v)$ was added to the dried resin. The column was left on a rocker for 2 h to cleave the peptide. The flow through from the column was collected and the resin was rinsed with TFA (1 mL). The combined cleavage mixture was added dropwise to cold diethyl ether (20 mL) in a centrifuge tube. The mixture was incubated on ice for 30 min. The precipitates were centrifuged for 5 min at 3000 rpm. Supernatant was decanted and the precipitates were washed with cold diethyl ether (10 mL). The centrifugation and washing steps were repeated for another two cycles. The precipitates were air-dried and then left under vacuum for overnight. Typical yield: 50−150 mg.

The procedure described above produced the *C*-terminal peptide amides. To generate peptides with carboxylic acid at the *C*-terminus, Wang resin was used instead. The procedure is similar as described above, except for the loading of the first amino acid. After swelling of Wang resin (300 mg, 0.59 mmol/g, 0.18 mmol) with CH_2Cl_2 (3 mL) for 15 min, the resin was resuspended in 9:1 (v/v) CH_2Cl_2/DMF (3.6) mL/0.4 mL). Fmoc-protected amino acid $(0.53 \text{ mmol}, 3 \text{ eq.})$ and HOAt $(72 \text{ mg}, 0.53 \text{ mmol}, 3 \text{ eq.})$ dissolved in a minimum amount of DMF were added to the resin. The mixture was agitated for 30 s. DIC (0.08 mL, 0.53 mmol, 3 eq.) was added to the resin followed by DMAP (2 mg, 0.02 mmol, 0.1 eq.) dissolved in a minimum amount of DMF. After 2 h of agitation, the unreacted hydroxyl groups were capped with acetic anhydride (0.03 mL, 0.35 mmol, 2 eq.) in the presence of pyridine (0.03 mL, 0.35 mmol, 2 eq.). The mixture was agitated for 30 min. The reagents were removed and the resin was washed with DMF $(4 \times 3 \text{ mL})$. Fmoc-deprotection, subsequent coupling of the amino acid, cleavage of peptide, and ether precipitation are identical as described for Rink Amide Am resin.

2. Purification of crude peptide

Crude peptide (40 mg) was dissolved in DMF (0.25 mL) and 0.1% aqueous TFA (0.25 mL). The solution was injected into a semi-preparative RP-HPLC system. A gradient of solvent A (MQ water, 0.1% (v/v) TFA) and solvent B (MeCN, 0.1% (v/v) TFA) was run at a flow rate of 12 mL/min as shown below. The fractions corresponding to the main peak were collected. MeCN was removed by evaporation under reduced pressure. The aqueous solution was lyophilized to yield the peptide as white powder (20−32 mg).

3. Representative example of synthesis of Man-peptide conjugates

SYWD (5.7 mg, 10 μ mol, 1 eq.) was dissolved in DMF (0.25 mL) followed by the addition of 200 mM MOPS (0.25 mL, pH 7.0). The solution was added to a 1.5-mL microcentrifuge tube containing sodium periodate (2.6 mg, 12 µmol, 1.2 eq.). The reaction mixture was incubated for 10 min at RT. To quench the oxidation, the solution was added to glutathione (37 mg, 120 µmol, 12 eq.) and mixed rapidly to ensure the dissolution of glutathione. After incubation for 10 min at RT, 2-(aminooxy)ethyl *α*-Dmannopyranoside (2.6 mg, 11 µmol, 1.1 eq.) dissolved in 200 mM anilinium acetate (0.25 mL, pH 4.7) was added to the quenched solution. The oxime ligation was carried out for 30 min at RT. The reaction mixture was injected into a semi-preparative RP-HPLC system. HPLC purification was carried out as described above for crude peptide to yield the product as a white fluffy powder (40−70% isolated yield) after lyophilization. The purity of the product was determined with an analytical RP-HPLC system (flow rate: 1 mL/min) using a gradient of solvent A (MQ water, 0.1% (v/v) TFA) and solvent B (MeCN, 0.1% (v/v) TFA) as shown below. The product was further characterized with HRMS (ESI).

Man-WYD (**L20**)

White fluffy powder (5.0 mg, 66% isolated yield): ¹H NMR (600MHz, deuterated PBS + 0.1% (v/v) DMSO-*d6*) δ = 7.61 (d, *J* = 7.9 Hz, 1 H), 7.56 (s, 1 H), 7.50 (d, *J* = 7.9 Hz, 1 H), 7.24 (t, *J* = 7.9 Hz, 1 H), 7.20 − 7.13 (m, 2 H), 6.96 (d, *J* = 8.1 Hz, 2 H), 6.74 (d, *J* = 8.1 Hz, 2 H), 4.88 (br. d, 1 H), 4.69 (t, *J* = 6.9 Hz, 1 H), 4.50 − 4.42 (m, 2 H), 4.41 − 4.33 (m, 2 H), 3.98 − 3.91 (m, 2 H), 3.83 - 3.75 (m, 3 H), 3.75 − 3.70 (m, 1 H), 3.66 (t, *J* = 9.6 Hz, 1 H), 3.62 − 3.56 (m, 1 H), 3.29 − 3.17 (m, 2 H), 2.92 (dd, *J* = 7.4, 13.9

Hz, 1 H), 2.79 (dd, *J* = 7.4, 13.9 Hz, 1 H), 2.60 (dd, *J* = 6.7, 16.0 Hz, 1 H), 2.50 (dd, *J* = 6.7, 16.0 Hz, 1 H); HRMS (ESI) calcd for $C_{34}H_{41}N_6O_{14}$ [M–H]⁻ $m/z = 757.2686$, found 757.2691.

4. Synthesis of Me-peptide conjugates

The synthesis and purification are identical to that of Man-peptides, other than the use of methoxylamine instead of 2-(aminooxy)ethyl *α*-D-mannopyranoside during the oxime ligation. Me-WYSVLSH (6.7 mg, 69% isolated yield) and Me-WYD (3.1 mg, 55% isolated yield) were obtained as a white fluffy powder. The purity of the products was determined with an analytical RP-HPLC system as described above. The products were further characterized with HRMS (ESI).

5. Synthesis of Man-NL-WYD (L20.3)

The synthesis and purification are identical to that of Man-peptides, other than the use of *O*-α-Dmannopyranosyl oxyamine instead of 2-(aminooxy)ethyl α -D-mannopyranoside during the oxime ligation. The product was obtained as a white fluffy powder $(4.3 \text{ mg}, 60\%$ isolated yield): ¹H NMR $(500MHz, D_2O + 0.1\%$ (v/v) DMSO- d_6) $\delta = 7.65$ (s, 1 H), 7.60 (d, *J* = 7.9 Hz, 1 H), 7.49 (d, *J* = 7.9 Hz, 1 H), 7.24 (t, *J* = 7.9 Hz, 1 H), 7.21 (s, 1 H), 7.16 (t, *J* = 7.9 Hz, 1 H), 6.93 (d, *J* = 8.4 Hz, 2 H), 6.74 (d, *J* = 8.4 Hz, 2 H), 5.53 (br. d, 1 H), 4.68 (t, *J* = 7.1 Hz, 1 H), 4.50 (t, *J* = 7.2 Hz, 1 H), 4.42 (t, *J* = 7.2 Hz, 1 H), 4.14 (dd, *J* = 1.9, 3.2 Hz, 1 H), 3.90 − 3.72 (m, 4 H), 3.68 − 3.60 (m, 1 H), 3.29 − 3.17 (m, 2 H), 2.86 − 2.72 (m, 3 H), 2.61 (dd, $J = 7.2$, 17.0 Hz, 1 H); HRMS (ESI) calcd for C₃₂H₃₇N₆O₁₃ [M–H]⁻ $m/z =$ 713.2424, found 713.2430.

6. Synthesis of Man-allyl-WYD (L20.4)

To a mixture of allyl bromide (12 μ L, 132 μ mol, 20 eq.) and indium (3 mg, 26 μ mol, 4 eq.), a solution of Man-WYD **L20** (5 mg, 6.6 µmol, 1 eq.) dissolved in DMF/H₂O/MeOH (200 µL, 1:1:2) was added. The mixture was agitated for 2 h at RT, after which, the solid was filtered. The filtrate was injected into a semi-preparative RP-HPLC system. HPLC purification was carried out as described above for crude peptide to yield the product as a white fluffy powder (2 mg, 38% isolated yield): 1 H NMR (500MHz, D₂O + 0.1% (v/v) DMSO-*d6*) δ = 7.62 (d, *J* = 7.7 Hz, 1 H), 7.48 (d, *J* = 8.3 Hz, 1 H), 7.26 − 7.20 (m, 2 H), 7.15 (t, *J* = 7.7 Hz, 1 H), 7.01 (d, *J* = 8.4 Hz, 2 H), 6.79 (d, *J* = 8.4 Hz, 2 H), 5.49 − 5.37 (m, 1 H), 5.03 − 4.92 (m, 2 H), 4.77 (br. d, 1 H), 4.71 − 4.65 (m, 1 H), 4.56 (t, *J* = 6.4 Hz, 1 H), 4.46 (t, *J* = 7.2 Hz, 1 H), 3.89 − 3.79 (m, 2 H), 3.75 − 3.69 (m, 2 H), 3.69 − 3.51 (m, 6 H), 3.51 − 3.44 (m, 1 H), 3.24 (dd, *J* = 7.2, 14.9 Hz, 1 H), 3.13 (dd, *J* = 7.2, 14.9 Hz, 1 H), 2.93 − 2.77 (m, 3 H), 2.71 − 2.65 (m, 1 H), 2.12 (t, *J* = 6.9 Hz, 2 H); HRMS (ESI) calcd for C₃₇H₄₇N₆O₁₄ [M–Na][−] *m*/z = 799.3156, found 799.3163.

7. Synthesis of Man-SL-WYD (L20.5)

The whole synthesis was carried out on resin as described above for solid-phase peptide synthesis. Briefly, Rink Amide AM resin (100 mg, 0.91 mmol g^{-1} , 0.09 mmol) was weighed into a Poly-Prep® chromatography column. After the swelling of the resin and Fmoc-deprotection, the resin was coupled with Fmoc-Asp(OtBu)-OH. The cycles of Fmoc-deprotection, amide coupling and washing step were repeated consecutively for Fmoc-Tyr(tBu)-OH and Fmoc-Trp(Boc)-OH. After the final Fmocdeprotection, carboxymethylthiopropyl α -D-mannopyranoside (74 mg, 0.18 mmol, 2 eq.) and DEPBT (54 mg, 0.18 mmol, 2 eq.) dissolved in DMF was added to the resin. After 30 s agitation, DIPEA (0.06 mL, 0.36 mmol, 4 eq.) was added to the mixture and the mixture was agitated for 2 h. The resin was washed with DMF (5 \times 3 mL), followed by CH₂Cl₂ (5 \times 3 mL). The resin was left on the manifold for 10 min to dry under the vacuum. A cleavage cocktail (1 mL) containing $TFA/H_2O/\text{phenol/TIPS}$ [85/5/5/5 (v/v/w/v)] was added to the dried resin. The column was left on a rocker for 2 h to cleave the peptide. The flow through from the column was collected and the resin was rinsed with TFA (1 mL). The combined cleavage mixture was added dropwise to cold diethyl ether (20 mL) in a centrifuge tube. The mixture was incubated on ice for 30 min. The precipitates were centrifuged for 5 min at 3000 rpm. Supernatant was decanted and the precipitates were washed with cold diethyl ether (10 mL). The centrifugation and

washing steps were repeated for another two cycles. The precipitates were air-dried and then left under vacuum for overnight. The crude solid was dissolved in DMF (0.25 mL) and 0.1% aqueous TFA (0.25 mL). The solution was injected into a semi-preparative RP-HPLC system. HPLC purification was carried out as described above for crude peptide to yield the product as to yield the product as white powder (35 mg, 50% isolated yield): HRMS (ESI) calcd for C₃₅H₄₄N₅O₁₃S [M−H]⁻ m/z = 774.2662, found 774.2656.

8. Synthesis of Man-WYK(Cy3)-OH

To a solution of Man-WYK-OH (4 mg, 5.2 µmol, 1 eq.) in DMSO/100 mM NaHCO₃ (400 µL, 1:1, pH 8.35), a solution of Cyanine3 NHS ester (3 mg, 5.2 µmol, 1 eq.) in DMSO (100 µL) was added. After three hours of reaction, the mixture was purified on semi-preparative RP-HPLC system. A gradient of solvent A (MQ water, 0.1% (v/v) TFA) and solvent B (MeCN, 0.1% (v/v) TFA) was run at a flow rate of 12 mL/min as shown below. The fractions corresponding to the main peak were collected. MeCN was removed by evaporation under reduced pressure. The aqueous solution was lyophilized to yield the product as red powder (4 mg, 58% isolated yield). HRMS (ESI) calcd for $C_{66}H_{83}N_8O_{14}$ [M]⁺ $m/z =$ 1211.6023, found 1211.6005.

HPLC purity and HRMS spectra of synthesized ligands

Peak Results

User Spectra

--- End Of Report ---

da Cale

Peak Results

User Spectra

R T	Area		Height % Area
8.570	46334	8413	0.94
	2 9.133 4861914 797620		99.06

User Spectra

User Spectra

Peak Results

User Spectra

User Spectra

Formula Calculator Results

275 300 325 350 375 400 425 450 475 500 525 550 575 600 625 650 675 700 725 750 775 800 825 850 875 900 925 Counts vs. Mass-to-Charge (m/z)

Formula Calculator Results

User Spectra

260 280 300 320 340 360 380 400 420 440 460 480 500 520 540 560 580 600 620 640 660 580 700 720 740 760 780 800 820 840

Formula Calculator Results

User Spectra

1 UUN INUUILU					
		Area		Height % Area	
		1 15.072 1428300 226982 100.00			

User Spectra

Formula Calculator Results

also Carloss

User Spectra

	RT	Area		Height % Area	
	11.028	235217	41881	7.66	
$\overline{2}$		11.341 2746172 413130		89.38	
3	11.508	91171	20455	2.97	

User Spectra

Peak Results					
	Height % Area Area RT				
	12.679	714360	91540	12.06	
2 ¹		13.521 5206632 714136		87.94	

User Spectra

 14.00

 12.00

 16.00

 18.00

 20.00

 2.00

 6.00

 8.00

 $10,00$

Minutes

 4.00

User Spectra

 0.05

 $0.00 -$

 0.00

User Spectra

RT	Area	Height	% Area
14.150	71969	12840	3.90
14.453	1731169 291871		93.92
14.676	40177	5200	2.18

User Spectra

Peak Results					
	RT	Area	Height % Area		
		12.056 2202027 114303		58.26	
		2 13.201 1577683 163947		41.74	

User Spectra

	RT	Area	Height	% Area I
	13.757	92139	15695	1.23
\mathcal{P}	13,980	7402957	1272477	98.77

User Spectra

--- End Of Report ---

÷

 \overline{a}

RT	Area	Height	% Area
	14.722 7441866 1314655		98.86
14.962	85621	14614	

User Spectra

Peak Results					
	RT	Area		Height % Area	
		14.584 10462628 1826071		93.66	
2 ¹	14.716	708711	137772	6.34	

User Spectra

RT	Area	Height	% Area
	14.600 9269927 1627337		97.71
14,799	216819	33477	2.29

User Spectra

 \mathbf{r} $\overline{}$

RT	Area	Height	% Area I
13.462	16117945 2720056		94.79
13.763	885592	152755	5.21

User Spectra

Peak Results					
	RT	Area	Height % Area		
		8.875 8290916 776943		96.25	
\overline{a}		18.389 323231 70076		3.75	

User Spectra

Supporting information references

- [1] M. Mayer, B. Meyer, *Angew. Chem. Int. Ed.* **1999**, *38*, 1784-1788.
- [2] M. Liu, X.-a. Mao, C. Ye, H. Huang, J. K. Nicholson, J. C. Lindon, *J. Magn. Reson.* **1998**, *132*, 125-129.
- [3] H. McWilliam, W. Li, M. Uludag, S. Squizzato, Y. M. Park, N. Buso, A. P. Cowley, R. Lopez, *Nucleic Acids Res.* **2013**, *41*, W597-W600.
- [4] F. P. Schwarz, K. D. Puri, R. G. Bhat, A. Surolia, *J. Biol. Chem.* **1993**, *268*, 7668-7677.
- [5] D. K. Mandal, C. F. Brewer, *Biochemistry* **1993**, *32*, 5116-5120.
- [6] S. Ng, M. R. Jafari, W. L. Matochko, R. Derda, *ACS Chem. Biol.* **2012**, *7*, 1482-1487.
- [7] O. Renaudet, P. Dumy, *Tetrahedron Lett.* **2001**, *42*, 7575-7578.
- [8] K. A. Noren, C. J. Noren, *Methods* **2001**, *23*, 169-178.
- [9] W. L. Matochko, S. Cory Li, S. K. Y. Tang, R. Derda, *Nucleic Acids Res.* **2014**, *42*, 1784-1798.
- [10] T. D. Schneider, R. M. Stephens, *Nucleic Acids Res.* **1990**, *18*, 6097-6100.
- [11] W. Kabsch, *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2010**, *66*, 125-132.
- [12] N. Collaborative Computational Project, *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **1994**, *50*, 760-763.
- [13] P. D. Adams, P. V. Afonine, G. Bunkoczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L.-W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger, P. H. Zwart, *Acta Crystallogr., Sect. D: Biol. Crystallogr.* **2010**, *66*, 213-221.
- [14] I. W. Davis, A. Leaver-Fay, V. B. Chen, J. N. Block, G. J. Kapral, X. Wang, L. W. Murray, W. B. Arendall, J. Snoeyink, J. S. Richardson, D. C. Richardson, *Nucleic Acids Res.* **2007**, *35*, W375-W383.
- [15] R. Kadirvelraj, B. L. Foley, J. D. Dyekjær, R. J. Woods, *J. Am. Chem. Soc.* **2008**, *130*, 16933- 16942.
- [16] M. O. Sinnokrot, E. F. Valeev, C. D. Sherrill, *J. Am. Chem. Soc.* **2002**, *124*, 10887-10893.
- [17] M. G. Ford, T. Weimar, T. Köhli, R. J. Woods, *Proteins: Structure, Function, and Bioinformatics* **2003**, *53*, 229-240.
- [18] D. A. Case, T. A. Darden, T. E. Cheatham, C. L. Simmerling, J. Wang, R. E. Duke, R. Luo, R. C. Walker, W. Zhang, K. M. Merz, B. Roberts, S. Hayik, A. Roitberg, G. Seabra, J. Swails, A. W. Goetz, I. Kolossváry, K. F. Wong, F. Paesani, J. Vanicek, R. M. Wolf, J. Liu, X. Wu, S. R. Brozell, T. Steinbrecher, H. Gohlke, Q. Cai, X. Ye, J. Wang, M.-J. Hsieh, G. Cui, R. D.R., M. D.H., S. M.G., R. Salomon-Ferrer, C. Sagui, V. Babin, T. Luchko, S. Gusarov, K. A., P. A. Kollman, *AMBER 12* **2012**, University of California, San Francisco.
- [19] A. W. Götz, M. J. Williamson, D. Xu, D. Poole, S. Le Grand, R. C. Walker, *J. Chem. Theory Comput.* **2012**, *8*, 1542-1555.
- [20] J.-P. Ryckaert, G. Ciccotti, H. J. C. Berendsen, *J. Comput. Phys.* **1977**, *23*, 327-341.
- [21] T. Darden, D. York, L. Pedersen, *J. Chem Phys.* **1993**, *98*, 10089-10092.
- [22] S. J. Hubbard, J. M. Thornton, *'NACCESS'* **1993**, Computer Program, Department of Biochemistry and Molecular Biology, University College London.
- [23] A. Onufriev, D. Bashford, D. A. Case, *Proteins: Structure, Function, and Bioinformatics* **2004**, *55*, 383-394.
- [24] K. T. Pilobello, P. Agrawal, R. Rouse, L. K. Mahal, *Curr. Protoc. Chem. Biol.* **2013**, *5*, 1-23.
- [25] C. Cheadle, M. P. Vawter, W. J. Freed, K. G. Becker, *J. Mol. Diagn.* **2003**, *5*, 73-81.
- [26] a) J. Sun, E. N. Kitova, W. Wang, J. S. Klassen, *Anal. Chem.* **2006**, *78*, 3010-3018; b) L. Deng, N. Sun, E. N. Kitova, J. S. Klassen, *Anal. Chem.* **2010**, *82*, 2170-2174.
- [27] I. Coin, M. Beyermann, M. Bienert, *Nat. Protocols* **2007**, *2*, 3247-3256.
- [28] Y.-W. Kim, T. N. Grossmann, G. L. Verdine, *Nat. Protocols* **2011**, *6*, 761-771.

NMR spectra of synthesized compounds

S108

S109

13 C DEPTQ NMR Spectra in D₂O, 150 MHz

f1 (ppm)